TrialReader


Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

NCT00544713 — Not applicable, Completed, 228 participants, Allergan

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT00544713
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: double, treatment
Enrollment228 (Actual)
SponsorAllergan (Industry)
ConditionsDry Eye Syndrome
InterventionsCarboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose (Drug)
Datesstart 2007-09-01, primary completion 2008-06-01, completion 2008-06-01, first posted 2007-10-16, last updated 2011-12-14
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Dry Eye Syndrome All trials of Carboxymethylcellulose and Glycerin based artificial tear All trials of Carboxymethylcellulose

-Summary

This study will evaluate the safety and efficacy of a new artificial tear for the treatment of dry eye that may occur after LASIK surgery

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Carboxymethylcellulose and Glycerin based artificial tearExperimentalDrug: Carboxymethylcellulose and Glycerin based artificial tearCarboxymethylcellulose and Glycerin based artificial tear
Carboxymethylcellulose based artificial tearActive comparatorDrug: CarboxymethylcelluloseCarboxymethylcellulose based artificial tear
  • Carboxymethylcellulose and Glycerin based artificial tear (Drug): As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
  • Carboxymethylcellulose (Drug), also known as Refresh Plus®: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake

+Outcome measures

Primary outcomes

  • Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90 [Day 90]: Measured on 12 domains (categories); a 5-point scale for each domain (0 = best, no dry eye symptoms, 4 = worst, constant dry eye symptoms). Sum of the domain scores is normalized (standardized) to a severity scale of 0-100 (0 = no symptoms (best score), 100 = maximum severity (worst score)).

Secondary outcomes

  • Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90 [Day 90]: A questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (referred to as AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".
  • Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90 [Day 90]: A patient acceptability - sensory questionnaire was administered to all patients to evaluate the acceptability of the Artificial Tears (AT). Percentage of patients responding either "Agree" or "Strongly Agree" at day 90 was tabulated. The potential response categories included "Strongly Agree", "Agree", "Neither Agree Nor Disagree", "Disagree" and "Strongly Disagree".
  • Best Corrected Visual Acuity (BCVA) Status at Day 90 [Day 90]: BCVA status at Day 90 reported as the number of patients whose scores were either "Better", "No Change", or "Worse" than their scores at baseline. The status was tabulated as number of lines read correctly at Day 90 minus the number of lines read correctly at baseline. "Better" equals increase of 2 lines or more; "No Change" equals change between -2 to +2 lines; "Worse" equals decrease of 2 lines or more. BCVA is measured using a special eye chart a nd is reported as the number of lines (5 letters per line) read correctly.
  • Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90 [Baseline, Day 90]: Change from Baseline in corneal topography of the worse eye as measured using a Pentacam system which calculates a number. Corneal topography is a non-invasive medical imaging technique for mapping the surface of the eye. The Pentacam system measures the pupil and anterior segment (the front part of the eye) which provides a range from 10 (best) to 60 (worst). A negative number change from baseline indicates an improvement.
  • Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90 [Baseline, Day 90]: Change from Baseline in corneal topography of the worse eye as measured by a Humphrey Atlas system which calculates a number. Corneal topography is anon-invasive medical imaging technique for mapping the surface curvature of the cornea (the outer structure of the eye). The higher the number the more irregular the cornea. A Humphrey Atlas system detects irregular conditions in the cornea with a range from 0 = best to 2.5 = worst. A negative number change from baseline indicates an improvement.
  • Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90 [Baseline, Day 90]: Change from Baseline in total HOA of the worse eye. The total HOA number is measured using a machine that calculates and detects changes in the cornea which could occur post Lasik surgery. A negative number change from baseline indicates an improvement.
  • Change From Baseline of the Worse Eye in Schirmer's Test at Day 90 [Baseline, Day 90]: Change from baseline in Schirmer's Test results at Day 90 in the worse eye. The Schirmer's Test measures the rate of the secretion of tears produced by the eye over 5 minutes. The results indicate the presence of dry eye (Normal = greater than or equal to 15 millimeters (mm) of tears, Dry Eye = less than 15 mm of tears). The smaller the number, the more severe the dry eye.
  • Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90 [Baseline, Day 90]: Change from Baseline in corneal staining of the worse eye at Day 90. Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), for a minimum score of 0 and a maximum score of 25. The higher the grade score, the worse the dry eye condition. A negative change from baseline represents a decrease in corneal staining (improvement).
  • Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90 [Baseline, Day 90]: Change from Baseline in conjunctival staining of the worse eye using Lissamine Green staining procedure. Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme (0 = no staining and 5 = severe staining), with a minimum score of 0 and a maximum score of 30. The higher the grade score, the worse dry eye condition. A negative number change from baseline represents a decrease in corneal staining (improvement).
  • Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90 [Baseline, Day 90]: Change from Baseline in TBUT of the worse eye at Day 90. TBUT is the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement).
  • Change From Baseline in Study Product Usage at Day 90 [Baseline, Day 90]: Change from baseline in the study product usage (average number of uses per day) at Day 90. A negative number change from baseline indicates a reduction in eye drop usage (improvement).

Other outcomes

  • Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60 [Day 14, Day 60]: Number of patients prescribed to each dosing regimen at Day 14 and Day 60. At each visit from Day 14 (the first post-operative visit) to Day 60, patients were prescribed to 1 to 4 dosing regimens based on the investigator's clinical evaluation. Dosing schedule options were: At least every 2 hours while awake, 6 to 8 times per day, 3 to 5 times per day, at 1 to 2 times per day.

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Candidate for bilateral LASIK surgery for myopia correction in the range of -1.00 to -8.00 diopters

Exclusion Criteria:

* Dry eye signs and symptoms
* Preoperative soft or rigid contact lens wear within last 7 or 30 days, respectively
* Pregnancy or planning pregnancy
* Uncontrolled systemic disease
* Use of systemic medications affecting dry eye

+Posted results

Participant flow

MilestoneCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Started114114
Completed111109
Not completed35

Outcome results

  • Post LASIK Dry Eye Symptoms as Measured by Ocular Surface Disease Index (OSDI©) Score at Day 90 (Primary), Mean, Scores on a Scale: Carboxymethylcellulose and Glycerin Based Artificial Tear 8.32 +/- 11.125; Carboxymethylcellulose Based Artificial Tear 6.43 +/- 8.036
  • Patient Acceptability- Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90 (Secondary), Number, Percentage of Patients: Carboxymethylcellulose and Glycerin Based Artificial Tear 88.4; Carboxymethylcellulose Based Artificial Tear 93.6
  • Patient Acceptability (Sensory) - Percentage of Patients Who Rated Artificial Tears (AT) as Acceptable at Day 90 (Secondary), Number, Percentage of Patients: Carboxymethylcellulose and Glycerin Based Artificial Tear 79.5; Carboxymethylcellulose Based Artificial Tear 87.2
  • Best Corrected Visual Acuity (BCVA) Status at Day 90 (Secondary), Number, Number of Patients: Carboxymethylcellulose and Glycerin Based Artificial Tear 8; Carboxymethylcellulose Based Artificial Tear 7
  • Change From Baseline of the Worse Eye in Corneal Topography as Measured by Pentacam at Day 90 (Secondary), Mean, Units on a scale: Carboxymethylcellulose and Glycerin Based Artificial Tear 31.95 +/- 11.941; Carboxymethylcellulose Based Artificial Tear 32.32 +/- 15.347
  • Change From Baseline of the Worse Eye in Corneal Topography Measured by Humphrey Atlas at Day 90 (Secondary), Mean, Units on a scale: Carboxymethylcellulose and Glycerin Based Artificial Tear 1.32 +/- 0.855; Carboxymethylcellulose Based Artificial Tear 1.25 +/- 0.456
  • Change From Baseline of Total Higher Order Aberration (HOA) of the Worse Eye at Day 90 (Secondary), Mean, Microns: Carboxymethylcellulose and Glycerin Based Artificial Tear 0.521 +/- 0.1842; Carboxymethylcellulose Based Artificial Tear 0.520 +/- 0.1845
  • Change From Baseline of the Worse Eye in Schirmer's Test at Day 90 (Secondary), Mean, Millimeters of Tears: Carboxymethylcellulose and Glycerin Based Artificial Tear 16.3 +/- 8.40; Carboxymethylcellulose Based Artificial Tear 13.5 +/- 6.30
  • Change From Baseline of the Worse Eye in Corneal Staining With Fluorescein at Day 90 (Secondary), Mean, Scores on a Scale: Carboxymethylcellulose and Glycerin Based Artificial Tear 0.5 +/- 1.13; Carboxymethylcellulose Based Artificial Tear 0.5 +/- 1.12
  • Change From Baseline of the Worse Eye in Conjunctival Staining With Lissamine Green at Day 90 (Secondary), Mean, Scores on a Scale: Carboxymethylcellulose and Glycerin Based Artificial Tear 1.0 +/- 1.98; Carboxymethylcellulose Based Artificial Tear 0.8 +/- 1.32
  • Change From Baseline of the Worse Eye in Tear Break-Up Time (TBUT) at Day 90 (Secondary), Mean, Number of seconds: Carboxymethylcellulose and Glycerin Based Artificial Tear 13.66 +/- 6.133; Carboxymethylcellulose Based Artificial Tear 13.25 +/- 5.250
  • Number of Patients Prescribed to Each Dosing Regimen at Day 14 and Day 60 (Other pre specified), Number, Number of patients: Carboxymethylcellulose and Glycerin Based Artificial Tear 20; Carboxymethylcellulose Based Artificial Tear 22
  • Change From Baseline in Study Product Usage at Day 90 (Secondary), Mean, Number of study product uses per day: Carboxymethylcellulose and Glycerin Based Artificial Tear 7.9 +/- 3.16; Carboxymethylcellulose Based Artificial Tear 7.9 +/- 4.89

Adverse events

ArmDeathsSerious adverse eventsOther adverse events
Carboxymethylcellulose and Glycerin Based Artificial Tear00/114 (0.0%)88/114 (77.2%)
Carboxymethylcellulose Based Artificial Tear00/114 (0.0%)82/114 (71.9%)

Other adverse events by term

TermOrgan systemCarboxymethylcellulose and Glycerin Based Artificial TearCarboxymethylcellulose Based Artificial Tear
Punctate KeratitisEye disorders21/11422/114
Halo VisionEye disorders10/1149/114
Dry EyeEye disorders10/1148/114
GlareEye disorders8/1147/114
Conjucntival HaemorrhageEye disorders8/1146/114
NasopharyngitisInfections and infestations8/1146/114
Eye Operation ComplicationsInjury, poisoning and procedural complications7/1145/114
Foreign Body Sensation in EyesEye disorders6/1146/114
PhotophobiaEye disorders5/1147/114
Ocular discomfortEye disorders5/1146/114

+Locations (1)

FacilityCityCountryStatus
San Diego, CaliforniaUnited States

+Investigators

  • Medical Director, Study director, Allergan

My Notes